<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92232">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01671254</url>
  </required_header>
  <id_info>
    <org_study_id>POT2-FMR-CT</org_study_id>
    <nct_id>NCT01671254</nct_id>
  </id_info>
  <brief_title>Effect of Citrus Bioflavonoids/Vitamin E in Conjunction With Fish Oil Supplementation</brief_title>
  <official_title>A Double-blind, Placebo-controlled Trial of a Dietary Supplement Containing Citrus Bioflavonoids and Vitamin E at 2 Doses in Conjunction With Fish Oil Supplementation in Hyperlipidemic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MetaProteomics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MetaProteomics LLC</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this 8-week intervention trial is to investigate the effect of a dietary
      supplement (containing citrus bioflavonoids and vitamin E) plus fish oil supplementation in
      healthy hyperlipidemic subjects
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>LDL cholesterol</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in LDL cholesterol level at the end of 8 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Triglyceride</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in triglyceride level at the end of 8 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>oxLDL</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in oxidized LDL level at the end of 8 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cholesterol</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in total cholesterol level at the end of 8 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL cholesterol</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in HDL cholesterol level at the end of 8 weeks.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>FishOil + placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this arm receive fish oil (EPA/DHA Extra Strength) and placebo capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FishOil + CBE75</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm receive fish oil (EPA/DHA Extra Strength) and citrus bioflavonoids+vitamin E (CBE)(75 mg/capsule/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FishOil + CBE150</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm receive fish oil (EPA/DHA Extra Strength) and CBE (150 mg/capsule/day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>FishOil</intervention_name>
    <arm_group_label>FishOil + placebo</arm_group_label>
    <arm_group_label>FishOil + CBE75</arm_group_label>
    <arm_group_label>FishOil + CBE150</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>CBE75</intervention_name>
    <arm_group_label>FishOil + CBE75</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>CBE150</intervention_name>
    <arm_group_label>FishOil + CBE150</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>FishOil + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  men and women ≥ 18 and ≤ 72 years old

          -  generally healthy

          -  BMI &gt; 18 and &lt; 38

          -  LDL cholesterol ≥ 130 mg/dl and &lt; 270 mg/dl

          -  triglycerides ≥ 150 mg/dl and &lt; 400 mg/dl

          -  ability to understand and the willingness to sign a written informed consent

        Exclusion Criteria:

          -  use of nutritional supplements and medical foods for dyslipidemia within 30 days
             prior to the study

          -  use of omega-3 fatty acid dietary supplements within 30 days prior to the study

          -  use of prescription HMG-CoA reductase inhibitors, bile acid sequestrants, fibrates,
             cholesterol absorption blocking agents, or niacin

          -  use of prescription medications and/or nonprescription medications for acute and
             semi-acute medical conditions

          -  history of cardiovascular disease, type i diabetes, autoimmune disease, liver or
             kidney disease, malignancy, and serious mental illness.

          -  known infection with HIB, TB, hepatitis B or hepatitis C

          -  history of allergy or intolerance to study products

          -  smoking, use of nicotine-containing products, or use of drugs of abuse 30 days prior
             to the study

          -  history of regular intake of &gt; 14 alcoholic drinks per week for females and &gt; 21
             drinks per week for males
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>72 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph J Lamb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MetaProteomics / Metagenics / FMRC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joseph J Lamb, MD</last_name>
    <phone>253-853-7207</phone>
    <email>josephlamb@metagenics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lincoln Bouillon, MBA</last_name>
    <phone>253-853-7206</phone>
    <email>lincolnbouillon@metagenics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Functional Medicine Research Center</name>
      <address>
        <city>Gig Harbor</city>
        <state>Washington</state>
        <zip>98332</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph J Lamb, MD</last_name>
      <phone>253-853-7207</phone>
      <email>josephlamb@metagenics.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 20, 2012</lastchanged_date>
  <firstreceived_date>August 20, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Alpha-Tocopherol</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
